{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T22:45:25Z","timestamp":1768085125911,"version":"3.49.0"},"reference-count":69,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aaojournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.ophtha.2021.11.024","type":"journal-article","created":{"date-parts":[[2021,12,3]],"date-time":"2021-12-03T21:13:42Z","timestamp":1638566022000},"page":"498-508","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["The 12- and 24-Month Effects of Intravitreal Ranibizumab, Aflibercept, and Bevacizumab on Intraocular Pressure"],"prefix":"10.1016","volume":"129","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7176-6631","authenticated-orcid":false,"given":"Keean","family":"Nanji","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gurkaran S.","family":"Sarohia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiandra","family":"Ceyhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tyler","family":"McKechnie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tahira","family":"Devji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lehana","family":"Thabane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5126-045X","authenticated-orcid":false,"given":"Peter","family":"Kaiser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Sarraf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunir J.","family":"Garg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sobha","family":"Sivaprasad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles C.","family":"Wykoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie J.","family":"Bakri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6370-1857","authenticated-orcid":false,"given":"Tom","family":"Sheidow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohit","family":"Bhandari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9988-4146","authenticated-orcid":false,"given":"Varun","family":"Chaudhary","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ophtha.2021.11.024_bib1","first-page":"546","article-title":"Update on the use of anti-VEGF intravitreal therapies for retinal vein occlusions","volume":"6","author":"Jiang","year":"2017","journal-title":"Asia-Pacific J Ophthalmol"},{"issue":"2","key":"10.1016\/j.ophtha.2021.11.024_bib2","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jcjo.2012.01.022","article-title":"Canadian Ophthalmological Society evidence-based clinical practice guidelines for the management of diabetic retinopathy\u2014executive summary","volume":"47","author":"Hooper","year":"2012","journal-title":"Can J Ophthalmol"},{"key":"10.1016\/j.ophtha.2021.11.024_bib3","author":"Dunbar Hoskins"},{"issue":"2","key":"10.1016\/j.ophtha.2021.11.024_bib4","doi-asserted-by":"crossref","first-page":"158","DOI":"10.4103\/jovr.jovr_50_18","article-title":"Intravitreal injection of anti-vascular endothelial growth factor agents for ocular vascular diseases: clinical practice guideline","volume":"13","author":"Nikkhah","year":"2018","journal-title":"J Ophthalmic Vis Res"},{"issue":"10","key":"10.1016\/j.ophtha.2021.11.024_bib5","first-page":"CD007419","article-title":"Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis","volume":"2018","author":"Virgili","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"10.1016\/j.ophtha.2021.11.024_bib6","first-page":"CD005139","article-title":"Anti-vascular endothelial growth factor for neovascular age-related macular degeneration","volume":"2019","author":"Solomon","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"10.1016\/j.ophtha.2021.11.024_bib7","first-page":"CD009510","article-title":"Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion","volume":"2020","author":"Shalchi","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"10.1016\/j.ophtha.2021.11.024_bib8","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.survophthal.2017.08.008","article-title":"The acute and chronic effects of intravitreal anti-vascular endothelial growth factor injections on intraocular pressure: a review","volume":"63","author":"Bracha","year":"2018","journal-title":"Surv Ophthalmol"},{"issue":"4","key":"10.1016\/j.ophtha.2021.11.024_bib9","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.ophtha.2018.11.019","article-title":"The effect of anti-vascular endothelial growth factor agents on intraocular pressure and glaucoma: a report by the American Academy of Ophthalmology","volume":"126","author":"Hoguet","year":"2019","journal-title":"Ophthalmology"},{"issue":"5","key":"10.1016\/j.ophtha.2021.11.024_bib10","doi-asserted-by":"crossref","first-page":"771","DOI":"10.5301\/ejo.5000455","article-title":"Effect of prophylactic medication and influence of vitreous reflux in pressure rise after intravitreal injections of anti-VEGF drugs","volume":"24","author":"Carnota-M\u00e9ndez","year":"2014","journal-title":"Eur J Ophthalmol"},{"issue":"7","key":"10.1016\/j.ophtha.2021.11.024_bib11","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1097\/IJG.0b013e3182948476","article-title":"Comparison of acetazolamide, brimonidine, and anterior chamber paracentesis for ocular hypertension control after initial intravitreal bevacizumab injection","volume":"23","author":"Katayama","year":"2014","journal-title":"J Glaucoma"},{"issue":"8","key":"10.1016\/j.ophtha.2021.11.024_bib12","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1097\/IJG.0b013e318294865c","article-title":"Ocular decompression with cotton swabs lowers intraocular pressure elevation after intravitreal injection","volume":"23","author":"Gregori","year":"2014","journal-title":"J Glaucoma"},{"issue":"3","key":"10.1016\/j.ophtha.2021.11.024_bib13","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1097\/IAE.0000000000000371","article-title":"Intraocular pressure trends after intravitreal injections of anti-vascular endothelial growth factor agents for diabetic macular edema","volume":"35","author":"Al-Abdullah","year":"2015","journal-title":"Retina"},{"issue":"10","key":"10.1016\/j.ophtha.2021.11.024_bib14","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1007\/s00417-012-1981-0","article-title":"Sustained elevation of intraocular pressure after intravitreal injections of bevacizumab in eyes with neovascular age-related macular degeneration","volume":"250","author":"Mathalone","year":"2012","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"6","key":"10.1016\/j.ophtha.2021.11.024_bib15","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1097\/IAE.0b013e318217ffde","article-title":"Sustained elevated intraocular pressures after intravitreal injection of bevacizumab, ranibizumab, and pegaptanib","volume":"31","author":"Choi","year":"2011","journal-title":"Retina"},{"issue":"5","key":"10.1016\/j.ophtha.2021.11.024_bib16","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.ophtha.2013.11.029","article-title":"Intraocular pressure in eyes receiving monthly ranibizumab in 2 pivotal age-related macular degeneration clinical trials","volume":"121","author":"Bakri","year":"2014","journal-title":"Ophthalmology"},{"issue":"7","key":"10.1016\/j.ophtha.2021.11.024_bib17","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1097\/IAE.0b013e31823f0c95","article-title":"A lack of delayed intraocular pressure elevation in patients treated with intravitreal injection of bevacizumab and ranibizumab","volume":"32","author":"Wehrli","year":"2012","journal-title":"Retina"},{"issue":"7","key":"10.1016\/j.ophtha.2021.11.024_bib18","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1097\/IJG.0b013e3182946505","article-title":"Does intravitreal injections of bevacizumab for age-related macular degeneration affect long-term intraocular pressure?","volume":"23","author":"Kim","year":"2014","journal-title":"J Glaucoma"},{"issue":"6","key":"10.1016\/j.ophtha.2021.11.024_bib19","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/j.ajo.2014.02.035","article-title":"Long-term effects of multiple intravitreal antivascular endothelial growth factor injections on intraocular pressure","volume":"157","author":"Kim","year":"2014","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"10.1016\/j.ophtha.2021.11.024_bib20","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1167\/iovs.10-6431","article-title":"Silicone oil microdroplets and protein aggregates in repackaged bevacizumab and ranibizumab: effects of long-term storage and product mishandling","volume":"52","author":"Liu","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"10.1016\/j.ophtha.2021.11.024_bib21","doi-asserted-by":"crossref","first-page":"28","DOI":"10.2174\/1874364101004010028","article-title":"Sustained intraocular pressure elevation after intravitreal injection of bevacizumab and ranibizumab associated\u00a0with trabeculitis","volume":"4","author":"Sniegowski","year":"2010","journal-title":"Open Ophthalmol J"},{"issue":"5","key":"10.1016\/j.ophtha.2021.11.024_bib22","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1097\/IAE.0000000000000520","article-title":"Sustained elevation of intraocular pressure after intravitreal anti-VEGF agents","volume":"35","author":"Dedania","year":"2015","journal-title":"Retina"},{"issue":"1","key":"10.1016\/j.ophtha.2021.11.024_bib23","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1089\/jop.2014.0062","article-title":"High intraocular pressure following anti-vascular endothelial growth factor therapy: proposed pathophysiology due to altered nitric oxide metabolism","volume":"31","author":"Ricca","year":"2015","journal-title":"J Ocul Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.ophtha.2021.11.024_bib24","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1167\/iovs.16-20786","article-title":"Intravitreal anti-VEGF injections reduce aqueous outflow facility in patients with neovascular age-related macular degeneration","volume":"58","author":"Wen","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"7","key":"10.1016\/j.ophtha.2021.11.024_bib25","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.oret.2020.02.007","article-title":"Anterior chamber angles after intravitreal injections for macular degeneration","volume":"4","author":"O\u2019Bryhim","year":"2020","journal-title":"Ophthalmol Retina"},{"issue":"4","key":"10.1016\/j.ophtha.2021.11.024_bib26","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1055\/s-0029-1245201","article-title":"Effect of brimonidine\/timolol fixed combination on preventing the short-term intraocular pressure increase after intravitreal injection of ranibizumab","volume":"227","author":"Theoulakis","year":"2010","journal-title":"Klin Monbl Augenheilkd"},{"issue":"8","key":"10.1016\/j.ophtha.2021.11.024_bib27","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1111\/j.1442-9071.2011.02565.x","article-title":"Safety profile of anterior chamber paracentesis performed at the slit lamp","volume":"39","author":"Trivedi","year":"2011","journal-title":"Clin Exp Ophthalmol"},{"issue":"1","key":"10.1016\/j.ophtha.2021.11.024_bib28","article-title":"Side effects of acetazolamide: a systematic review and meta-analysis assessing overall risk and dose dependence","volume":"7","author":"Schmickl","year":"2020","journal-title":"BMJ Open Respir Res"},{"issue":"suppl","key":"10.1016\/j.ophtha.2021.11.024_bib29","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/0039-6257(83)90140-6","article-title":"Side effects of timolol","volume":"28","author":"Zimmerman","year":"1983","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.ophtha.2021.11.024_bib30","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1097\/IAE.0000000000000399","article-title":"Intravitreal injection technique and monitoring: updated guidelines of an expert panel","volume":"34","author":"Avery","year":"2014","journal-title":"Retina"},{"issue":"3","key":"10.1016\/j.ophtha.2021.11.024_bib31","first-page":"A17","article-title":"Age-related eye diseases: an emerging challenge for public health professionals","volume":"2","author":"Gohdes","year":"2005","journal-title":"Prev Chronic Dis"},{"issue":"9","key":"10.1016\/j.ophtha.2021.11.024_bib32","first-page":"1430","article-title":"Diabetes and risk of glaucoma: systematic review and a meta-analysis of prospective cohort studies","volume":"10","author":"Zhao","year":"2017","journal-title":"Int J Ophthalmol"},{"issue":"1","key":"10.1016\/j.ophtha.2021.11.024_bib33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/srep39301","article-title":"Sustained elevation of intraocular pressure associated with intravitreal administration of anti-vascular endothelial growth factor: a systematic review and meta-analysis","volume":"6","author":"Zhou","year":"2016","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.ophtha.2021.11.024_bib34","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s11739-016-1583-7","article-title":"Network meta-analysis: an introduction for clinicians","volume":"12","author":"Rouse","year":"2017","journal-title":"Intern Emerg Med"},{"issue":"4","key":"10.1016\/j.ophtha.2021.11.024_bib35","first-page":"333","article-title":"Network meta-analysis to synthesize evidence for decision making in cardiovascular research","volume":"106","author":"Roever","year":"2016","journal-title":"Arq Bras Cardiol"},{"issue":"2","key":"10.1016\/j.ophtha.2021.11.024_bib36","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","article-title":"Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: An overview and tutorial","volume":"64","author":"Salanti","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.ophtha.2021.11.024_bib37","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/1741-7015-9-79","article-title":"Network meta-analysis-highly attractive but more methodological research is needed","volume":"9","author":"Li","year":"2011","journal-title":"BMC Med"},{"key":"10.1016\/j.ophtha.2021.11.024_bib38","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ophtha.2021.11.024_bib39","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1159\/000459691","article-title":"Intravitreal steroids in diabetic macular edema","volume":"60","author":"Lattanzio","year":"2017","journal-title":"Dev Ophthalmol"},{"key":"10.1016\/j.ophtha.2021.11.024_bib40","doi-asserted-by":"crossref","first-page":"989501","DOI":"10.1155\/2014\/989501","article-title":"Intravitreal steroids for the treatment of retinal diseases","volume":"2014","author":"Sarao","year":"2014","journal-title":"ScientificWorldJournal"},{"issue":"7829","key":"10.1016\/j.ophtha.2021.11.024_bib41","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.ophtha.2021.11.024_bib42","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1080\/10618600.1998.10474787","article-title":"Alternative methods for monitoring convergence of iterative simulations","volume":"7","author":"Brooks","year":"1998","journal-title":"J Comput Graph Stat"},{"issue":"1","key":"10.1016\/j.ophtha.2021.11.024_bib43","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/jrsm.1167","article-title":"Automated generation of node-splitting models for assessment of inconsistency in network meta-analysis","volume":"7","author":"van Valkenhoef","year":"2016","journal-title":"Res Synth Methods"},{"key":"10.1016\/j.ophtha.2021.11.024_bib44","doi-asserted-by":"crossref","first-page":"g5630","DOI":"10.1136\/bmj.g5630","article-title":"A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis","volume":"349","author":"Puhan","year":"2014","journal-title":"BMJ"},{"key":"10.1016\/j.ophtha.2021.11.024_bib45","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jclinepi.2017.10.005","article-title":"Advances in the GRADE approach to rate the certainty in estimates from a network meta-analysis","volume":"93","author":"Brignardello-Petersen","year":"2018","journal-title":"J Clin Epidemiol"},{"issue":"19","key":"10.1016\/j.ophtha.2021.11.024_bib46","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1001\/jama.2019.5790","article-title":"Effect of initial management with aflibercept vs laser photocoagulation vs observation on vision loss among patients with diabetic macular edema involving the center of the macula and good visual acuity: a randomized clinical trial","volume":"321","author":"Baker","year":"2019","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.ophtha.2021.11.024_bib47","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ophtha.2008.10.018","article-title":"Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR Study","volume":"116","author":"Brown","year":"2006","journal-title":"Ophthalmology"},{"issue":"9900","key":"10.1016\/j.ophtha.2021.11.024_bib48","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/S0140-6736(13)61501-9","article-title":"Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial","volume":"382","author":"Chakravarthy","year":"2013","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.ophtha.2021.11.024_bib49","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1016\/j.ophtha.2015.08.006","article-title":"Outcomes with as-needed ranibizumab after initial monthly therapy: long-term outcomes of the phase III RIDE and RISE trials","volume":"122","author":"Boyer","year":"2015","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.ophtha.2021.11.024_bib50","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1001\/jamaophthalmol.2018.6776","article-title":"Effect of ranibizumab and aflibercept on best-corrected visual acuity in treat-and-extend for neovascular age-related macular degeneration: a randomized clinical trial","volume":"137","author":"Gillies","year":"2019","journal-title":"JAMA Ophthalmol"},{"issue":"10","key":"10.1016\/j.ophtha.2021.11.024_bib51","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1016\/j.ophtha.2015.06.017","article-title":"Intravitreal aflibercept for diabetic macular edema: 100-week results from the VISTA and VIVID studies","volume":"122","author":"Brown","year":"2015","journal-title":"Ophthalmology"},{"issue":"11","key":"10.1016\/j.ophtha.2021.11.024_bib52","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1001\/jamaophthalmol.2019.3305","article-title":"Clinical effectiveness of intravitreal therapy with ranibizumab vs aflibercept vs bevacizumab for macular edema secondary to central retinal vein occlusion: a randomized clinical trial","volume":"137","author":"Hykin","year":"2019","journal-title":"JAMA Ophthalmol"},{"issue":"4","key":"10.1016\/j.ophtha.2021.11.024_bib53","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.ophtha.2011.01.031","article-title":"The RESTORE Study","volume":"118","author":"Mitchell","year":"2011","journal-title":"Ophthalmology"},{"issue":"7","key":"10.1016\/j.ophtha.2021.11.024_bib54","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1016\/j.ophtha.2015.02.006","article-title":"The REVEAL study: ranibizumab monotherapy or combined with laser versus laser monotherapy in Asian patients with diabetic macular edema","volume":"122","author":"Ishibashi","year":"2015","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1016\/j.ophtha.2021.11.024_bib56","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s00417-018-04213-x","article-title":"Efficacy and safety of ranibizumab 0.5 mg in Chinese patients with visual impairment due to diabetic macular edema: results from the 12-month REFINE study","volume":"257","author":"Li","year":"2019","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.ophtha.2021.11.024_bib57","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1016\/j.ophtha.2017.06.027","article-title":"Sustained benefits of ranibizumab with or without laser in branch retinal vein occlusion: 24-month results of the BRIGHTER Study","volume":"124","author":"Tadayoni","year":"2017","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1016\/j.ophtha.2021.11.024_bib58","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.ophtha.2010.02.031","article-title":"Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema","volume":"117","author":"Elman","year":"2010","journal-title":"Ophthalmology"},{"issue":"20","key":"10.1016\/j.ophtha.2021.11.024_bib59","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1056\/NEJMoa1102673","article-title":"Ranibizumab and bevacizumab for neovascular age-related macular degeneration","volume":"364","author":"Martin","year":"2011","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ophtha.2021.11.024_bib60","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.ajo.2007.10.004","article-title":"Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1","volume":"145","author":"Regillo","year":"2008","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"10.1016\/j.ophtha.2021.11.024_bib61","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.ophtha.2010.09.004","article-title":"Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study","volume":"118","author":"Schmidt-Erfurth","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2021.11.024_bib62","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1001\/jamaophthalmol.2017.6843","article-title":"Comparison of monthly vs treat-and-extend regimens for individuals with macular edema who respond well to anti-vascular endothelial growth factor medications: secondary outcomes from the SCORE2 randomized clinical trial","volume":"136","author":"Scott","year":"2018","journal-title":"JAMA Ophthalmol"},{"issue":"1","key":"10.1016\/j.ophtha.2021.11.024_bib63","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.oret.2019.08.001","article-title":"Efficacy and safety of ranibizumab in Asian patients with branch retinal vein occlusion: results from the randomized BLOSSOM study","volume":"4","author":"Wei","year":"2020","journal-title":"Ophthalmol Retina"},{"issue":"13","key":"10.1016\/j.ophtha.2021.11.024_bib64","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1056\/NEJMoa1414264","article-title":"Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema","volume":"372","author":"Wells","year":"2015","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ophtha.2021.11.024_bib65","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.jcjo.2014.12.014","article-title":"Efficacy\/safety of ranibizumab monotherapy or with laser versus laser monotherapy in DME","volume":"50","author":"Berger","year":"2015","journal-title":"Can J Ophthalmol"},{"issue":"6","key":"10.1016\/j.ophtha.2021.11.024_bib66","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/j.ophtha.2010.03.045","article-title":"A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study). 12-Month data: report 2","volume":"117","author":"Michaelides","year":"2010","journal-title":"Ophthalmology"},{"issue":"9","key":"10.1016\/j.ophtha.2021.11.024_bib67","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1016\/j.ophtha.2015.04.018","article-title":"Intraocular pressure in patients with neovascular age-related macular degeneration receiving intravitreal aflibercept or ranibizumab","volume":"122","author":"Freund","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2021.11.024_bib68","author":"Sch\u00fcnemann"},{"key":"10.1016\/j.ophtha.2021.11.024_bib69","doi-asserted-by":"crossref","first-page":"m3907","DOI":"10.1136\/bmj.m3907","article-title":"GRADE approach to drawing conclusions from a network meta-analysis using a partially contextualised framework","volume":"371","author":"Brignardello-Petersen","year":"2020","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.ophtha.2021.11.024_bib70","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-020-70269-7","article-title":"The effects of intravitreal injections on intraocular pressure and retinal nerve fiber layer: a systematic review and meta-analysis","volume":"10","author":"de Vries","year":"2020","journal-title":"Sci Rep"}],"container-title":["Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642021009179?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642021009179?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T14:12:00Z","timestamp":1758982320000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161642021009179"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":69,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S0161642021009179"],"URL":"https:\/\/doi.org\/10.1016\/j.ophtha.2021.11.024","relation":{},"ISSN":["0161-6420"],"issn-type":[{"value":"0161-6420","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The 12- and 24-Month Effects of Intravitreal Ranibizumab, Aflibercept, and Bevacizumab on Intraocular Pressure","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ophtha.2021.11.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 by the American Academy of Ophthalmology","name":"copyright","label":"Copyright"}]}}